Empowering Breast Cancer Treatment
Product Name: Tukysa
Brand Name: Tukysa
Active Ingredient: Tucatinib
Strength: 50 mg/tablet and 150 mg/tablet
Manufacturer Name: Genentech
List of excipients:
- Lactose monohydrate
- Microcrystalline cellulose
- Magnesium stearate
- Colloidal silicon dioxide
- Titanium dioxide (E171)
- Yellow iron oxide (E172)
Why is Kineret injection prescribed?
The prescription medicine KINERET (anakinra), commonly known as an interleukin-1 receptor antagonist (IL-1Ra), is only available to adults over the age of 18 to:
To administer Kineret, a subcutaneous injection is used.
Kineret is provided in a graduated prefilled syringe and is ready for use. Using the graduated prefilled syringe, doses between 20 and 100 mg are possible. The syringe is inappropriate for pediatric patients with a body weight below 10 kg because the minimum dose is 20 mg.
Who should not take KINERET?
If you’re unsure, speak with your doctor.
What are the possible side effects of KINERET?
Severe possible side effects of KINERET include:
What documents are required to import KINERET to Dubai?
The following paperwork is necessary to import:
Special Precautions For Kineret
Tukysa (tucatinib) is a prescription medication used to treat adult patients with HER2-positive breast cancer that is locally advanced or metastatic (has spread to other parts of the body). Tukysa is taken in combination with trastuzumab and capecitabine.
Special storage precautions:
· Tukysa should be stored at room temperature (between 68°F and 77°F) in a tightly closed container.
· Tukysa should not be stored in the bathroom or near a heat source.
· Tukysa should be stored in the original carton to protect it from light.
· Tukysa is a targeted therapy that works by blocking the HER2 protein, which is found on the surface of cancer cells.
· Tukysa has been shown to significantly improve the progression-free survival (PFS) of patients with HER2-positive breast cancer.
· Tukysa is generally well-tolerated, with the most common side effects being diarrhea, nausea, vomiting, and hand-foot syndrome.
· Tukysa is available as film-coated tablets in two strengths: 50 mg and 150 mg.
· The recommended dosage of Tukysa is 300 mg taken orally twice daily in combination with trastuzumab and capecitabine.
· Tukysa should be taken with food.
· Tukysa is not recommended for patients with severe liver impairment.
· Tukysa should be taken under the supervision of a healthcare professional.
· Patients should read the Tukysa Medication Guide carefully before starting treatment.
· Patients should tell their healthcare professional about all of their medical conditions, including allergies, other medications they are taking, and their pregnancy plans.
· Patients should monitor their weight and report any changes to their healthcare professional.
· Patients should contact their healthcare professional immediately if they experience any serious side effects.
We are a leading pharmaceutical wholesaler, Hayat Alhikmah, situated in Dubai. By providing generic medications, reference listed drugs, name patient import services, and temperature-controlled products simple to access for our consumers, we help them overcome geographic distances.
We offer affordable access to anakinra injection in Dubai with ease and speed. Depending on the customer’s needs, we provide a quality guarantee and shipping anywhere in the world.
Please schedule a consultation with us by calling us at +971 54 777 1238 or email us at [email protected] to know how much anakinra injection costs in Dubai. Our helpful team would be happy to assist you and provide any general or medical information.
Tukysa should not be taken by patients with severe liver impairment. Tukysa should also be avoided by patients who are allergic to tucatinib or any of the ingredients in Tukysa.
Tukysa should be stored at room temperature (between 68°F and 77°F) in a tightly closed container. Tukysa should not be stored in the bathroom or near a heat source.
Tukysa has been shown to significantly improve the progression-free survival (PFS) of patients with HER2-positive breast cancer that is locally advanced or metastatic. In a clinical study, Tukysa-treated patients had a median PFS of 16.4 months, compared to 9.3 months for patients who received placebo.
Tukysa is taken orally twice daily in combination with trastuzumab and capecitabine. The recommended dosage of Tukysa is 300 mg.
Tukysa can cause serious side effects, including diarrhea, nausea, vomiting, and hand-foot syndrome. Other side effects that may occur with Tukysa include:
- Dry skin
- Decreased appetite
- Weight loss
- Changes in taste
- Changes in vision
- Decreased white blood cell count
- Increased liver enzymes
- Decreased kidney function